Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 57.4% and a total average
Truist Financial Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $48
Piper Sandler analyst Yasmeen Rahimi maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 3
Edgewise Therapeutics To Host Webcast Event To Discuss Top-Line Data From Phase 1 Trial In Healthy Subjects And Phase 2 CIRRUS-HCM Trial In Patients With Obstructive HCM On Thursday, September 19 at 8:30 Am ET
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $32
RBC Capital analyst Leonid Timashev maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 45
Edgewise Jumps Ahead of "Key Stock-moving Event"